MYC and hepatocellular carcinoma: While Dasatinib has been studied in HCC cell lines,12, 18 whether Dasatinib is effective against c‐Myc over expressing HCC cells and whether c‐Myc and/or p‐Lyn could be used as biomarker for Dasatinib sensitivity in HCC have not been previously characterized.